KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

Astrazeneca (AZN) Other Non Operating Income (2016 - 2025)

Historic Other Non Operating Income for Astrazeneca (AZN) over the last 15 years, with Q3 2025 value amounting to $349.0 million.

  • Astrazeneca's Other Non Operating Income rose 2737.23% to $349.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 billion, marking a year-over-year decrease of 209.95%. This contributed to the annual value of $1.3 billion for FY2021, which is 3443.28% up from last year.
  • As of Q3 2025, Astrazeneca's Other Non Operating Income stood at $349.0 million, which was up 2737.23% from $371.0 million recorded in Q2 2025.
  • Astrazeneca's Other Non Operating Income's 5-year high stood at $371.0 million during Q2 2025, with a 5-year trough of $265.0 million in Q1 2025.
  • Over the past 5 years, Astrazeneca's median Other Non Operating Income value was $319.0 million (recorded in 2021), while the average stood at $316.2 million.
  • Within the past 5 years, the most significant YoY rise in Astrazeneca's Other Non Operating Income was 2737.23% (2025), while the steepest drop was 1225.17% (2025).
  • Astrazeneca's Other Non Operating Income (Quarter) stood at $335.0 million in 2021, then dropped by 12.54% to $293.0 million in 2022, then increased by 25.26% to $367.0 million in 2023, then fell by 25.34% to $274.0 million in 2024, then increased by 27.37% to $349.0 million in 2025.
  • Its Other Non Operating Income was $349.0 million in Q3 2025, compared to $371.0 million in Q2 2025 and $265.0 million in Q1 2025.